Global Cell Therapy Market Report and Forecast 2024-2032

Global Cell Therapy Market Share

Market Segmentation by Cell Type is Expected to Drive Substantial Market Growth

Based on the cell type, the market is segmented into stem cells and non-stem cells. The stem cell segment comprises bone marrow derived mesenchymal stem cells, hematopoietic stem cells, umbilical cord derived stem cells, adipose derived stem cells, skin stem cells, and induced pluripotent stem cells, among others, whereas non-stem cells segment includes dendritic cells and car t-cells.

The increasing application of stem cells in regenerative medicine and treatment of various diseases is poised to support the cell therapy market growth. Bone marrow derived mesenchymal stem cells (BM-MSC) are taken from bone marrow. They have the ability to differentiate into various cell types and are useful in treating bone and cartilage diseases, and cardiovascular conditions. On the other hand, hematopoietic stem cells (HSC) are taken from bone marrow, peripheral blood, or umbilical cord blood. These cells are responsible for blood cell formation and are increasingly used in the treatment of blood disorders such as leukemia, lymphoma, and anemia.

The cell therapy market is also experiencing increased interest in non-stem cell therapies including dendritic cells and CAR T-cells. Such cell therapies are utilized in cancer immunotherapy to destroy cancer cells by leveraging the body's immune system. This segment is anticipated to drive significant market demand with the rising cases of cancer and the need for effective treatment approaches.

North America and Europe are Leading the Market Share

Historically, North America dominated the cell therapy market due to the presence of adequate financial support from both government and private bodies in the development of novel cell therapy products and the increased awareness and acceptance of cell therapies among healthcare providers and patients. In the United States, the rising burden of chronic diseases (such as heart disease, cancer, diabetes, obesity, and hypertension) drives the demand for advanced therapies. The US Department of Health and Human Services estimated that around 129 million people in the United States have at least 1 major chronic disease. Since cell therapies can offer promising treatment options for these chronic conditions, the market share is expected to grow in the coming years. Thus, the cell therapy market in North America, particularly in the United States, is anticipated to witness steady growth owing to increased demand for effective cell therapies, growing interest in regenerative medicine and personalized treatment approaches, and rising regulatory support for innovative treatments.

Europe also holds a significant share of the overall cell therapy industry, with France and the United Kingdom being some of the dominant regional markets. The increasing research and development activities in France, owing to the presence of some of the leading biotech and research institutions of cell therapy, are bolstering the market growth. In addition, the French biotech institutions, with government support, are contributing to the development of innovative cell therapies. Moreover, the introduction of various favorable government initiatives to aid research activities is invigorating the industry growth, hence contributing to the overall growth of the cell therapy market in the European region. For instance, the United Kingdom government initiated the Human-Induced Pluripotent Stem Cells Initiative (HipSCi) to bring preclinical, clinical, and pharmacological work on stem cells under one institution and increase the accessibility of induced pluripotent stem cell (iPSC) resources to identify new mechanisms.

Cell Therapy Market Report Snapshots

Cell Therapy Market Size

Cell Therapy Market Trends

Cell Therapy Market Share

Cell Therapy Companies